Article citationsMore>>

Chianella, C., Gragnaniello, D., Delser, P.M., Visentini, M.F., Sette, E., Tola, M.R., Barbujani, G. and Fuselliet, S. (2011) BCHE and CYP2D6 Genetic Variation in Alzheimer’s Disease Patients Treated with Cholinesterase Inhibitors. European Journal of Clinical Pharmacology, 67, 1147-1157.
http://dx.doi.org/10.1007/s00228-011-1064-x

has been cited by the following article:

• TITLE: Prevalence of Wild-Type Butyrylcholinesterase Genotype in Patients with Alzheimer’s Dementia

  AUTHORS: Beate Mueller, Georg Adler

  KEYWORDS: Butyrylcholinesterase, Alzheimer’s Disease, Genotype

  JOURNAL NAME: World Journal of Neuroscience, Vol.5 No.3, June 2, 2015

  ABSTRACT: Approximately, two-thirds patients with Alzheimer’s disease (AD) are reported to have homozygous wild-type butyrylcholinesterase (BuChE) gene expression. It is associated with a higher rate of hydrolysis of acetylcholine, which ultimately leads to increase in the levels of BuChE in advanced stages of the disease. Rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and BuChE, might be of additional benefit in patients with AD with wild-type BuChE allele.